Skip to content

Xeris Pharmaceuticals

US · XERS #2862 by market cap Listed 2018
16.97 +0.35 +2.11%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:57

Quant vs Street three independent views, side by side

StockVane factor grade
C-
Momentum strategy signal
Hold
Analyst consensus
Buy

Mostly aligned, one view stands apart.

Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.

Analyst consensus 6 analysts

Buy
Avg price target 16.50 -2.8%
Price target rangecurrent 16.97
Low8.00
Avg16.50
High21.00
Buy 83% Hold 17% Sell 0%
Recent ratings (25)
DateFirmAnalystRatingTarget
2026-11-11 Barclays -- Buy 18.00
2026-11-09 H.C. Wainwright -- Buy 18.00
2026-11-06 Craig-Hallum -- Buy 18.00
2026-11-06 H.C. Wainwright -- Buy 18.00
2026-11-06 Oppenheimer -- Buy 21.00
2026-10-06 Barclays -- Buy 14.00
2026-09-29 Craig-Hallum -- Buy 12.00
2026-09-21 H.C. Wainwright -- Buy 10.00
2026-09-10 Craig-Hallum -- Buy 12.00
2026-09-10 Piper Sandler -- Hold 8.00
2026-09-10 Leerink Partners -- Buy 16.00
2026-09-10 H.C. Wainwright -- Buy 10.00
2026-08-20 Barclays -- Buy 12.00
2026-08-07 Piper Sandler -- Hold 8.00
2026-08-07 H.C. Wainwright -- Buy 10.00
2026-07-08 Craig-Hallum -- Buy 12.00
2026-06-30 Craig-Hallum -- Buy --
2026-06-11 Craig-Hallum -- Buy --
2026-05-13 Barclays -- Buy 9.00
2026-05-08 Craig-Hallum -- Buy 12.00
2026-05-08 H.C. Wainwright -- Buy 10.00
2026-05-06 Craig-Hallum -- Buy --
2026-04-28 Craig-Hallum -- Buy 12.00
2026-03-19 Barclays -- Buy 9.00
2026-03-03 Craig-Hallum -- Buy --

Price target trend monthly average, last 3 years

Earnings history price reaction on the day

PeriodReport dateSessionOptions expectedActual move
2026/Q3 2026-11-05 -- ±17.66% +25.05% (beat)
2026/Q2 2026-08-06 -- ±17.02% -9.25% (in line)
2026/Q1 2026-05-07 -- ±15.70% +4.08% (in line)
2025/Q4 2026-03-02 -- ±23.00% -1.63% (in line)
2025/Q3 2025-11-06 -- ±14.65% -21.88% (beat)
2025/Q2 2025-08-07 -- ±14.75% +20.22% (beat)
2025/Q1 2025-05-08 -- ±17.63% +15.18% (in line)
2024/Q4 2025-03-06 -- ±40.00% +9.55% (in line)
2024/Q3 2024-11-08 -- ±32.44% +3.27% (in line)
2024/Q2 2024-08-08 -- ±26.76% +4.69% (in line)
2024/Q1 2024-05-09 -- ±30.27% +1.62% (in line)
2023/Q4 2024-03-06 -- ±27.60% -19.48% (in line)

"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.

Quote time 2026-11-20 19:57:17 · For reference only, not investment advice and not tailored to your situation.

Xeris Pharmaceuticals discussion 0 comments

Add a comment